Single Agent Regorafenib in First-line for Metastatic/Unresectable KIT/PDGFR Wild Type GIST
NCT02638766
Interventional
Phase 2
Completed
REGISTRI
Evaluate the treatment with regorafenib in patients with metastatic and/or unresectable KIT/PDGFR wild type GIST in the first line setting.
Nov 30,2015
All
18 Years
N/A
18 Years
N/A
15